Thursday, 20 Sep 2018

You are here

PRECISION Subanalyses Question Aspirin Use

The PRECISION trial reported last year that celecoxib appears to be safer than the NSAIDs naproxen or ibuprofen in treating osteoarthritis (OA) and rheumatoid arthritis patients who are at increased cardiovascular risk. New data suggests that adding aspirin may nullify this advantage according to a study presented at the 2017 American Heart Association  (AHA) meeting and reported by Medscape.

A subanalysis of the 24,000 patients from the PRECISION trial was conducted to look at those who also took aspirin.

For those not taking aspirin, naproxen or ibuprofen had significantly greater risk of major adverse CV events (MACE), non-CV death, gastrointestinal (GI) events, and renal events than those receiving celecoxib.

The ibuprofen group also had significantly greater risk for MACE alone, for GI events, and for renal events vs the study-drug group; while the naproxen group had significantly greater risk for just GI and renal events.

The subanalyses shows that for those who take aspirin, the risk for the composite end point and for renal events was significantly greater only for the ibuprofen group; the risk for GI events was still greater for both groups vs those receiving celecoxib; and there were no longer any significant between-group differences in risk for MACE alone.

The presenting authors suggest that "you shouldn't take aspirin if you dont need aspirin".

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Managing Comorbidity and Poor Drug Responses

Comorbidity is pervasive and complicates medical care in general. It can be a by-product of aging. It may result from drug therapy or an inciting disease process and may be part of the constellation that defines the primary disorder. A growing body of evidence that suggests that comorbidity has a significant dampening effect on drug responsiveness and, adds to poorer outcomes in patients with inflammatory arthritis.

Opioid Aversion is Augmenting Spinal Steroid Injections

As physicians turn away from opioids, are they resorting to options that may also be unsafe?

The New York Times reports that some physicians are using the anti-inflammatory drug, Depo-Medrol, for intraspinal injections to manage painful spinal and perispinal disorders.

Company Payments to Rheumatologists, Specialists Linked to Increased ACTH Prescriptions

Despite its exorbitant price tag and paucity of supportive clinical evidence, ACTH (corticotropin) sales have increased in the United States. A recent JAMA article examined its use by specialists and found that those who prescribe ACTH (including rheumatologists, nephrologists, neurologists) received corticotropin-related payments from the products sole manufacturer, Mallinckrod.

Veterans Administration Shuns Marijuana as an Option

Cannabis therapy is legal in 30 states in the US, and soon to be legal in Canada and Great Britian, but the US Veterans Administration continues to reject medical marijuana as a therapeutic option - even in states where it is approved.

Predictors of Methotrexate Non-Response

New research from a UK study suggests that nonresponse to oral or subcutaneous MTX was seen in 43% and is predicted by seronegativity, higher disease activity measures and higher anxiety scores.